文献速递免疫规划妇幼与学校卫生

评估志贺菌疫苗对生长结局的影响及对临床试验设计的启示

Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design.
PubMed 文献 · Vaccine · 2026-07-15

本研究基于多站点腹泻研究的模拟参数,比较了按随机疫苗组直接比较生长结局与在自然感染亚组中估计疫苗效应的检验效能。

要点

  • 按随机疫苗组直接比较HAZ的效能极低(<15%),且可能因随机机会出现反向结果。

核心结论

  • 现实规模的临床试验可能不足以检出疫苗对生长的影响,但采用自然感染亚组估计并优化试验设计可提高检出效应并降低无效或反向结果的风险。

研究设计与样本

  • 基于多站点腹泻研究参数化的模拟研究,比较自然感染亚组与全研究人群检出线性生长效应的效能。
  • 进一步量化免疫程序、研究站点和生长测量时机等试验设计选择对效能的影响。

主要发现

  • 按随机疫苗组直接比较HAZ在现实试验规模(n=2500至20000)下效能极低(<15%),且存在因随机机会显示反向效应的风险。

关键数值与推荐

  • 直接比较HAZ的效能<15%(现实试验规模n=2500至20000)。

临床怎么用

  • 在志贺菌疫苗临床试验中可考虑采用自然感染亚组估计生长效应,并优化免疫程序与生长测量时机以提高效能。

局限性

  • 结果基于模拟研究,参数来源于多站点腹泻研究,可能受模型假设影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value proposition for Shigella vaccines is strengthened by the potential for vaccines to prevent linear growth faltering. However, because expected effect sizes in Phase 3 vaccine trials are small due to limited Shigella incidence, a simple comparison of growth by randomized vaccine arm is likely underpowered and may yield null or even inverse results. METHODS: We consider a new approach that estimates vaccine effects in the subgroup that would be infected in absence of vaccination, termed the naturally infected. In simulations parameterized by multi-site studies of diarrhea, we compare power for detecting linear growth effects in the naturally infected versus the full study. We further quantified how power is impacted by trial design choices including immunization schedule, study site, and timing of growth measurements. FINDINGS: Simple comparisons of height-for-age z-score (HAZ) by randomized vaccine arm have extremely limited power (<15%) at realistic trial sizes (n=2500 to 20,000) and carry risk of showing an inverse effect due to random chance. In contrast, naturally infected effects were often five to ten times larger and power was up to three times higher. Using a twelve month immunization schedule with a single growth endpoint in high-incidence settings maximized power to detect an effect. INTERPRETATIONS: While realistically sized clinical trials may be underpowered to detect an effect of vaccination on growth, estimation using the naturally infected subpopulation and careful trial design improve chances of detecting an effect while mitigating risks of null or inverse results.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Codi A, Rogawski McQuade E, Benkeser D, et al. Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design. Vaccine. 2026. PMID: 42456559. doi:10.1016/j.vaccine.2026.128908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。